Nordic Life Science 1
Monica Shaw CEO of Oncopeptides Johan Färnstrand
Director General of Lif Sweden Peter Hovstadius CMO of XNK Therapeutics MONICA SHAW replaces Jakob Lindberg, who assumes his previous position as Chief Scientific Officer. Shaw brings executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to commercialization, globally and across many geographies. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, encompassing immunology, oncology, virology, neurology and rare diseases. “I am thrilled to join Oncopeptides and drive the commercialization of Pepaxti in Europe at this exciting time and become engaged in the development of the preclinical portfolio,” says Shaw. “I look forward to working with the team to ensure that patients with multiple myeloma, who continue to need new treatment options, can get access to, and benefit from, Pepaxti.” JOHAN FÄRNSTRAND has during the last couple of years been heading Swedish healthcare activities at Aleris and CEO of Aleris Sjukvård. He has previously been Regional Director in Gävleborg and before that he held leading positions within Uppsala Municipal Council, the media industry and at SAS, as well as several board assignments. He studied Business Administration at Uppsala University and holds a MBA from Stockholm School of Economics. “The industry is completely central to the development of the healthcare sector, and developments within medical innovation and precision medicine imply that we are facing a paradigm shift. At the same time we are facing challenges when new effective treatments are not reaching the patients, where they bring real benefit. I look forward to continue to develop Swedish healthcare, but now from a new perspective,” says Färnstrand. PETER HOVSTADIUS received his MD from Uppsala University in 1992 and his PhD in Preclincal and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment in 2005. He is also a specialist in Clinical Pharmacology. He has held MD positions at several global research-based pharma companies, leading large organizations and being part of launching new therapies. Most recently, he spent eight years as CSO at Novartis Nordics. He also pioneered the role as Chief Innovation Officer at Novartis, establishing new industry collaborations between pharma and innovative startup companies in the expanding e-Health sector. “XNK is moving quickly in the exciting field of NK cell-based therapies,” says Hovstadius. “I’m looking forward to developing the company’s clinical programs and increase clinical collaborations,” he adds. Sissel Lønning Andresen CEO of LINK Medical SISSEL LØNNING ANDRESEN has a Master of Science in pharmacy and has been working in the pharmaceutical industry since 1998, holding several positions within regulatory, sales, marketing, market access, and public affairs. For the last nine years, she has been the CEO of Pfizer Norway. Prior to this, she held several different roles at Pfizer and has also worked at Pharmacia and GE Healthcare. “I’m thrilled and humbled to start the role as new CEO of LINK Medical at such a pivotal time and I look forward to meeting my new colleagues across all departments. Together with the highly skilled staff, we will build and develop the company into its next chapter of growth,” says Lønning Andresen. Ola Gudmundsen will remain in the company in a strategic role, where he will work closely with Sissel and support the Business Development and Commercial Operations team. 16 | NORDICLIFESCIENCE.ORG